Yousif Capital Management LLC Reduces Stock Holdings in Pfizer Inc. (NYSE:PFE)

Yousif Capital Management LLC lowered its position in Pfizer Inc. (NYSE:PFE - Free Report) by 1.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 639,552 shares of the biopharmaceutical company's stock after selling 10,695 shares during the quarter. Yousif Capital Management LLC's holdings in Pfizer were worth $16,206,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Lipe & Dalton raised its position in Pfizer by 17.7% in the fourth quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company's stock valued at $71,000 after purchasing an additional 400 shares during the period. Beam Wealth Advisors Inc. increased its position in shares of Pfizer by 1.5% during the 4th quarter. Beam Wealth Advisors Inc. now owns 27,444 shares of the biopharmaceutical company's stock worth $728,000 after purchasing an additional 401 shares during the last quarter. Providence Capital Advisors LLC raised its holdings in Pfizer by 0.4% in the 4th quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company's stock valued at $3,034,000 after buying an additional 409 shares during the period. Donaldson Capital Management LLC raised its holdings in Pfizer by 1.2% in the 4th quarter. Donaldson Capital Management LLC now owns 35,694 shares of the biopharmaceutical company's stock valued at $947,000 after buying an additional 410 shares during the period. Finally, Noesis Capital Mangement Corp lifted its position in Pfizer by 2.6% in the fourth quarter. Noesis Capital Mangement Corp now owns 16,357 shares of the biopharmaceutical company's stock valued at $434,000 after buying an additional 413 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PFE has been the subject of a number of recent analyst reports. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. UBS Group increased their price objective on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Cantor Fitzgerald assumed coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 target price on the stock. The Goldman Sachs Group restated a "neutral" rating and set a $25.00 price target (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Finally, Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Stock Up 1.2%

NYSE:PFE traded up $0.30 during midday trading on Wednesday, reaching $24.60. The company had a trading volume of 10,963,035 shares, compared to its average volume of 40,922,426. The stock's fifty day simple moving average is $22.93 and its 200-day simple moving average is $24.98. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The firm has a market capitalization of $139.83 billion, a price-to-earnings ratio of 17.46, a PEG ratio of 0.64 and a beta of 0.57.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business's revenue for the quarter was down 7.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.82 earnings per share. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 6.99%. Pfizer's dividend payout ratio (DPR) is currently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.